Atossa Genetics Inc (NASDAQ:ATOS) shares traded down 6.7% during trading on Monday . The company traded as low as $2.70 and last traded at $2.78. 527,279 shares were traded during mid-day trading, a decline of 81% from the average session volume of 2,816,989 shares. The stock had previously closed at $2.98.
Several equities analysts recently commented on the stock. Maxim Group reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Atossa Genetics in a research report on Tuesday, March 26th. ValuEngine upgraded Atossa Genetics from a “buy” rating to a “strong-buy” rating in a report on Friday, March 15th.
The stock has a market capitalization of $24.35 million, a P/E ratio of -0.47 and a beta of 3.82.
An institutional investor recently bought a new position in Atossa Genetics stock. Barclays PLC bought a new position in Atossa Genetics Inc (NASDAQ:ATOS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 32,384 shares of the company’s stock, valued at approximately $33,000. Barclays PLC owned approximately 0.57% of Atossa Genetics at the end of the most recent reporting period. 8.59% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Atossa Genetics (ATOS) Trading Down 6.7%” was originally reported by Modern Readers and is owned by of Modern Readers. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.modernreaders.com/news/2019/04/17/atossa-genetics-atos-trading-down-6-7.html.
Atossa Genetics Company Profile (NASDAQ:ATOS)
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Featured Article: What is a Call Option?
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.